Metabolic and body composition changes after six months of highly active antiretroviral therapy in northern Indian patients

International Journal of STD and AIDS

Volumn 22, Issue 1, 2011, Pages 46-49

  Gupta, V ^a   Biswas, A ^a   Sharma, S K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bioelectrical impedance; CART; Dyslipidemia; HIV AIDS; Hypertension; Metabolic syndrome; North indian

Indexed keywords

CHOLESTEROL; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE PLUS EFAVIRENZ; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ANTHROPOMETRY; ARM CIRCUMFERENCE; ARTICLE; BICEP SKINFOLD THICKNESS; BODY COMPOSITION; BODY FAT; BODY MASS; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HIGH DENSITY CHOLESTEROL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP CIRCUMFERENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPEDANCE; INDIAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; PREHYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKINFOLD THICKNESS; SUBSCAPULAR SKINFOLD THICKNESS; SUPRAILIAC SKINFOLD THICKNESS; SURVIVAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRICEP SKINFOLD THICKNESS; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INDIA; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 79952264091     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2010.010193     Document Type: Article

References (28)

1. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-6 (Pubitemid 30437589)
2. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy: results from the DAD study. AIDS 2003;17:1179-93 (Pubitemid 36667761)
3. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9 (Pubitemid 32150958)
4. Palella F, Wang Z, Chu H, et al. Correlates and prevalence of the metabolic syndrome over time in the Multicenter AIDS Cohort Study (MACS) [Abstract]. IAS Conf HIV Pathog Treat 2005;3rd:Abstract no. TuPe2.2B18
5. Misra A, Vikram NK. Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition 2004;20:482-91 (Pubitemid 38501805)
6. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72 (Pubitemid 37430158)
7. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and the management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005;112:2735-52 (Pubitemid 41532612)
8. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62
9. American Diabetes Association. Standards of medical care in diabetes -2008. Diabetes Care 2008;31(Suppl 1):12-54
10. US National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report. JAMA 2001;285:2486-97
11. Department of AIDS Control, Ministry of Health and Family Welfare, Government of India. Annual Report 2009-10. See: http://nacoonline.org/upload/ AR%202009-10/NACO-AR-English%20corrected.pdf (last accessed 23 December 2010)
12. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Côte d'Ivoire. N Engl J Med 2006;355:1141-53 (Pubitemid 44394920)
13. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-34 (Pubitemid 41713744)
14. Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 2004;36:967-71 (Pubitemid 38944093)
15. Froguel P. Tracking down genes to cure diabetes: an achievable task for the 21st century? Diabetes Metab 1997;23(Suppl 2):813
16. Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C. Weight and body shape changes in a treatment-naïve population after 6 months of nevirapine-based generic highly active antiretroviral therapy in south India. CID 2007;44:295-300 (Pubitemid 46079998)
17. Bamshad M, Kivisild T, Watkins WS, et al. Genetic evidence on the origins of Indian caste populations. Genome Res 2001;11:994-1004 (Pubitemid 32834545)
18. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004;292:191-201 (Pubitemid 38917996)
19. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-weeks results of a randomized study. J Acquir Immune Defic Syndr 2007;44:139-47 (Pubitemid 46292215)
20. Dube MP, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naïve participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual x-ray absorptiometry results from A5005s, a subset of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007;45:508-14 (Pubitemid 47294922)
21. Mallon PWG, Miller J, Cooper DA, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003;17:971-9 (Pubitemid 36549708)
22. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in western India. J Acquir Immune Defic Syndr 2005;39:199-202
23. van Leth F, Phanuphak P, Gazzard B, et al. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NNStudy) [abstract752]. In: Program and Abstracts of the10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria: Foundation for Retrovirology and Human Health, 2003
24. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52
25. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24:416-20 (Pubitemid 24201271)
26. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596-601 (Pubitemid 28090690)
27. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-9 (Pubitemid 32681162)
28. Wasir JS, Misra A, Vikram NK, Pandey RM, Gupta R. Comparison of definitions of the metabolic syndrome in adult Asian Indians. JAPI 2008;56:158-64